Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Is second-line anti-tuberculosis drug susceptibility testing reliable?

S J Kim, M A Espinal, C Abe

    The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease
    |October 1, 2004
    PubMed
    Summary

    No abstract available in PubMed .

    Related Experiment Videos

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Key operational challenges at a programmatic level to achieve optimal use of the GeneXpert platform.

    IJTLD open·2026
    Same author

    Fifteen years of rifampicin-resistant TB control in Niger: high countrywide treatment uptake and success.

    IJTLD open·2026
    Same author

    High-dose amikacin in the first week of all-oral rifampicin-resistant TB treatment is safe: a single-arm trial.

    IJTLD open·2025
    Same author

    Using linezolid as a substitute for the injectable in case of ototoxicity is safer and as effective as all-oral treatment for rifampicin-resistant TB.

    IJTLD open·2025
    Same author

    Reply to Schön et al., "Quality control and considering systematic MIC shifts are key when evaluating the role of <i>mmpR5</i> (<i>Rv0678</i>) frameshifts in bedaquiline resistance".

    Antimicrobial agents and chemotherapy·2025
    Same author

    Phenotypic and genotypic resistance to bedaquiline in patients with multi-drug-resistant tuberculosis-experiences from Armenia.

    Antimicrobial agents and chemotherapy·2025